Cited by 233Cannabis and Cannabinoid ResearchSubstance Abuse Treatment and OutcomesSmoking Behavior and Cessation

The DOI matches its Crossref record; 63 of the 64 references it cites were found in a registry or an index.

Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial.

Open access

Levin, Frances R., Mariani, John J., Brooks, Daniel J., Pavlicova, Martina, Cheng, Wendy, Nunes, Edward V.·2011·Drug and Alcohol Dependence

DOI 10.1016/j.drugalcdep.2010.12.010PMC PMC3154755

Open this paper in CoChat — free account

Abstract

Cannabis dependence is a substantial public health problem. Behavioral treatments have shown promise, but there are no effective medications for cannabis dependence. The purpose of this study was to evaluate the safety and efficacy of dronabinol, a synthetic form of delta-9-tetrahydrocannabinol, a naturally occurring pharmacologically active component of marijuana, in treating cannabis dependence. 156 cannabis-dependent adults were enrolled in a randomized, double-blind, placebo-controlled, 12-week trial. After a 1-week placebo lead-in phase, participants were randomized to receive dronabinol 20mg twice a day or placebo. Doses were maintained until the end of week 8 and then tapered off over 2 weeks. All participants received weekly motivational enhancement and relapse prevention therapy. Marijuana use was assessed using the timeline follow back method. There was no significant difference between treatment groups in the proportion of participants who achieved 2 weeks of abstinence at the end of the maintenance phase (dronabinol: 17.7%; placebo: 15.6%). Although both groups showed a reduction in marijuana use over time, there were no differences between the groups. Treatment retention was significantly higher at the end of the maintenance phase on dronabinol (77%), compared to placebo (61%) (P=.02), and withdrawal symptoms were significantly lower on dronabinol than placebo (P=.02). This is the first trial using an agonist substitution strategy for treatment of cannabis dependence. Dronabinol showed promise, it was well-tolerated, and improved treatment retention and withdrawal symptoms. Future trials might test higher doses, combinations of dronabinol with other medications with complementary mechanisms, or with more potent behavioral interventions.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.drugalcdep.2010.12.010

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
Timeline Follow-Back
Sobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110
Diagnostic and Statistical Manual of Mental Disorders
Raber, G., & Spokas, M. (2024) · doi:10.4135/9781071886229.n145 · Cited by 2,806
Nicotine replacement therapy for smoking cessation
Stead, L. F., Perera, R., Bullen, C., Mant, D., Hartmann‐Boyce, J., Cahill, K., & Lancaster, T. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000146.pub4 · Cited by 2,564
Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence: The COMBINE Study: A Randomized Controlled Trial
Anton, R. F., O’Malley, S. S., Ciraulo, D. A., Cisler, R. A., Couper, D., Donovan, D. M., Gastfriend, D. R., Hosking, J. D., Johnson, B. A., LoCastro, J. S., et al. (2006) · JAMA · doi:10.1001/jama.295.17.2003 · Cited by 1,930
Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002209.pub2 · Cited by 1,654
The Cannabis Youth Treatment (CYT) Study: Main findings from two randomized trials
Dennis, M. L., Godley, S. H., Diamond, G., Tims, F. M., Babor, T. F., Donaldson, J., Liddle, H. A., Titus, J. C., Kaminer, Y., Webb, C. P. M., et al. (2004) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2003.09.005 · Cited by 780
Nicotine replacement therapy for smoking cessation
Stead, L. F., Perera, R., Bullen, C., Mant, D., & Lancaster, T. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000146.pub3 · Cited by 721 · cited 2×
“…varenicline, methadone, buprenorphine) reduce withdrawal symptoms, improve treatment retention, reduce the reinforcing effects of the addictive drug, and promote abstinence (Comer et al., 2001; Garrison and Dugan, 2009; Mattick et al., 2009; Schottenfeld et al., 2008; Stead et al., 2008).”
Background
Comparison of extended versus brief treatments for marijuana use.
Stephens, R. S., Roffman, R. A., & Curtin, L. (2000) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.68.5.898 · Cited by 711
Prevalence of Marijuana Use Disorders in the United States: 1991-1992 and 2001-2002
Compton, W. M., Grant, B. F., Colliver, J. D., Glantz, M. D., & Stinson, F. S. (2004) · JAMA · doi:10.1001/jama.291.17.2114 · Cited by 537

Show all 64 references

Sorted by citations

Cannabis use and cannabis use disorder
Connor, J. P., Stjepanović, D., Le Foll, B., Hoch, E., Budney, A. J., & Hall, W. D. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00247-4 · Cited by 552
Keep off the grass? Cannabis, cognition and addiction
Curran, H. V., Freeman, T. P., Mokrysz, C., Lewis, D. A., Morgan, C. J. A., & Parsons, L. H. (2016) · Nature reviews. Neuroscience · doi:10.1038/nrn.2016.28 · Cited by 389
BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
Neuroscience of Addiction: Relevance to Prevention and Treatment
Volkow, N. D., & Boyle, M. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17101174 · Cited by 389
A Double-Blind Randomized Controlled Trial of N -Acetylcysteine in Cannabis-Dependent Adolescents
Gray, K. M., Carpenter, M. J., Baker, N. L., DeSantis, S. M., Kryway, E., Hartwell, K. J., McRae-Clark, A. L., & Brady, K. T. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12010055 · Cited by 306
Nabiximols as an Agonist Replacement Therapy During Cannabis Withdrawal: A Randomized Clinical Trial
Allsop, D. J., Copeland, J., Lintzeris, N., Dunlop, A. J., Montebello, M., Sadler, C., Rivas, G. R., Holland, R. M., Muhleisen, P., Norberg, M. M., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.3947 · Cited by 266
A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults.
Mason, B. J., Crean, R., Goodell, V., Light, J. M., Quello, S., Shadan, F., Buffkins, K., Kyle, M., Adusumalli, M., Begovic, A., et al. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.14 · Cited by 242
The cannabis withdrawal syndrome: current insights
Bonnet, U., & Preuss, U. (2017) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s109576 · Cited by 221
Treatment of Cannabis Use Disorder: Current Science and Future Outlook
Sherman, B. J., & McRae‐Clark, A. L. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1747 · Cited by 223
A review of co‐morbid tobacco and cannabis use disorders: Possible mechanisms to explain high rates of co‐use
Rabin, R. A., & George, T. P. (2015) · American Journal on Addictions · doi:10.1111/ajad.12186 · Cited by 210
Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial
D’Souza, D. C., Cortes-Briones, J., Creatura, G. M., Bluez, G., Thurnauer, H., Deaso, E., Forselius-Bielen, K., Surti, T. S., Radhakrishnan, R., Gupta, A., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30427-9 · Cited by 195
Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications.
Bilbao, A., & Spanagel, R. (2022) · BMC Medicine · doi:10.1186/s12916-022-02459-1 · Cited by 181
Extended-Release Mixed Amphetamine Salts vs Placebo for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cocaine Use Disorder: A Randomized Clinical Trial
Levin, F. R., Mariani, J. J., Specker, S., Mooney, M., Mahony, A., Brooks, D. J., Babb, D., Bai, Y., Eberly, L. E., Nunes, E. V., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.41 · Cited by 179
Self-citation
Anxiety and Substance Use Disorders: Co-occurrence and Clinical Issues
Vorspan, F., Mehtelli, W., Dupuy, G., Bloch, V., & Lépine, J. (2015) · Current Psychiatry Reports · doi:10.1007/s11920-014-0544-y · Cited by 189
Pharmacotherapies for cannabis dependence.
Marshall, K., Gowing, L., Ali, R., & Le Foll, B. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008940.pub2 · Cited by 156
The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal
Brezing, C., & LEVIN, F. R. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.212 · Cited by 148
Self-citation
Risks Associated With the Non-Medicinal Use of Cannabis
Hoch, E., Bonnet, U., Thomasius, R., Ganzer, F., Havemann‐Reinecke, U., & Preuss, U. W. (2015) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2015.0271 · Cited by 142
How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review
Hoch, E., Niemann, D., von Keller, R., Schneider, M., Friemel, C. M., Preuss, U. W., Hasan, A., & Pogarell, O. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-00984-4 · Cited by 131
The Endocannabinoid System and Cannabidiol's Promise for the Treatment of Substance Use Disorder
Chye, Y., Christensen, E., Solowij, N., & Yücel, M. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00063 · Cited by 132
State of the Art Treatments for Cannabis Dependence
Danovitch, I., & Gorelick, D. A. (2012) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2012.03.003 · Cited by 129
Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial
Trigo, J. M., Soliman, A., Quilty, L. C., Fischer, B., Rehm, J. T., Selby, P. L., Barnes, A. J., Huestis, M. A., George, T. P., Streiner, D. L., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0190768 · Cited by 123
Clinical management of cannabis withdrawal
Connor, J. P., Stjepanović, D., Budney, A. J., Foll, B. L., & Hall, W. (2021) · Addiction · doi:10.1111/add.15743 · Cited by 128
Nabiximols for the Treatment of Cannabis Dependence
Lintzeris, N., Bhardwaj, A. K., Mills, L., Dunlop, A. J., Copeland, J., McGregor, I. S., Bruno, R., Gugusheff, J., Phung, N., Montebello, M. E., et al. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.1993 · Cited by 111
Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial.
Levin, F. R., Mariani, J. J., Pavlicova, M., Brooks, D., Glass, A., Mahony, A., Nunes, E. V., Bisaga, A., Dakwar, E., Carpenter, K. M., et al. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.11.025 · Cited by 109
Self-citation
Predictors of Marijuana Relapse in the Human Laboratory: Robust Impact of Tobacco Cigarette Smoking Status
Haney, M., Bedi, G., Cooper, Z. D., Glass, A., Vosburg, S. K., Comer, S. D., & Foltin, R. W. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.07.028 · Cited by 111
Alcohol, tobacco, and marijuana consumption is associated with increased odds of same-day substance co- and tri-use
Roche, D. J. O., Bujarski, S., Green, R., Hartwell, E. E., Leventhal, A. M., & Ray, L. A. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.02.035 · Cited by 106
The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users
Vandrey, R. G., Stitzer, M. L., Mintzer, M. Z., Huestis, M. A., Murray, J. A., & Lee, D. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.08.001 · Cited by 106
ASRA Pain Medicine consensus guidelines on the management of the perioperative patient on cannabis and cannabinoids
Shah, S., Schwenk, E. S., Sondekoppam, R. V., Clarke, H. A., Zakowski, M. I., Lynn, R. R., Yeung, B., Nicholson, K., Schwartz, G. S., Hooten, W. M., et al. (2023) · Regional Anesthesia & Pain Medicine · doi:10.1136/rapm-2022-104013 · Cited by 113
The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone
Bisaga, A. M., Sullivan, M. A., Glass, A., Mishlen, K., Pavlicová, M., Haney, M., Raby, W. N., LEVIN, F. R., Carpenter, K. M., Mariani, J. J., et al. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.05.013 · Cited by 102
Self-citation
Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings.
Trigo, J. M., Lagzdins, D., Rehm, J., Selby, P., Gamaleddin, I., Fischer, B., Barnes, A. J., Huestis, M. A., & Le Foll, B. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.02.020 · Cited by 97
Pharmacotherapies for cannabis dependence
Nielsen, S., Gowing, L., Sabioni, P., & Le Foll, B. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008940.pub3 · Cited by 96
Combining cognitive behavioral therapy and contingency management to enhance their effects in treating cannabis dependence: less can be more, more or less.
Carroll, K. M., Nich, C., LaPaglia, D. M., Peters, E. N., Easton, C. J., & Petry, N. M. (2012) · Addiction · doi:10.1111/j.1360-0443.2012.03877.x · Cited by 91
Risks and Benefits of Cannabis and Cannabinoids in Psychiatry
Hill, K. P., Gold, M. S., Nemeroff, C. B., McDonald, W. M., Grzenda, A. L., Widge, A. S., Rodríguez, C. I., Kraguljac, N. V., Krystal, J. H., & Carpenter, L. L. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.21030320 · Cited by 96
A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders.
Levin, F. R., Mariani, J., Brooks, D. J., Pavlicova, M., Nunes, E. V., Agosti, V., Bisaga, A., Sullivan, M. A., & Carpenter, K. M. (2013) · Addiction · doi:10.1111/add.12108 · Cited by 89
Self-citation
The endocannabinoid system as a target for addiction treatment: Trials and tribulations
Sloan, M. E., Gowin, J. L., Ramchandani, V. A., Hurd, Y. L., & Foll, B. L. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.05.031 · Cited by 94
Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers: Nabilone in marijuana smokers
Bedi, G., Cooper, Z. D., & Haney, M. (2013) · Addiction Biology · doi:10.1111/j.1369-1600.2011.00427.x · Cited by 83
Cannabinoid abuse and addiction: Clinical and preclinical findings
Panlilio, L. V., Goldberg, S. R., & Justinová, Z. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.118 · Cited by 74
Topiramate and motivational enhancement therapy for cannabis use among youth: a randomized placebo‐controlled pilot study
Miranda, R., Padovano, H. T., Blanchard, A., Justus, A. N., Monti, P. M., Chun, T. H., Swift, R. M., Tidey, J. W., & Gwaltney, C. J. (2016) · Addiction Biology · doi:10.1111/adb.12350 · Cited by 74
Medicinal Uses of Marijuana and Cannabinoids
Grotenhermen, F., & Müller‐Vahl, K. (2016) · Critical Reviews in Plant Sciences · doi:10.1080/07352689.2016.1265360 · Cited by 72
Naltrexone Maintenance Decreases Cannabis Self-Administration and Subjective Effects in Daily Cannabis Smokers.
Haney, M., Ramesh, D., Glass, A., Pavlicova, M., Bedi, G., & Cooper, Z. D. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.108 · Cited by 73
Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial
McRae‐Clark, A. L., Baker, N. L., Gray, K. M., Killeen, T. K., Wagner, A. M., Brady, K. T., DeVane, C. L., & Norton, J. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.08.013 · Cited by 77
Cannabinoid Hyperemesis Syndrome: A Case Series and Review of Previous Reports
Nicolson, S. E., Denysenko, L., Mulcare, J. L., Vito, J., & Chabon, B. (2012) · Psychosomatics · doi:10.1016/j.psym.2012.01.003 · Cited by 69
Pharmacologic management of comorbid post-traumatic stress disorder and addictions
Shorter, D. I., Hsieh, J. J., & Kosten, T. R. (2015) · American Journal on Addictions · doi:10.1111/ajad.12306 · Cited by 65
Consideration of sex and gender differences in addiction medication response
McKee, S. A., & McRae‐Clark, A. L. (2022) · Biology of Sex Differences · doi:10.1186/s13293-022-00441-3 · Cited by 67
Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders
Galaj, E., & Xi, Z. (2019) · CNS Drugs · doi:10.1007/s40263-019-00664-w · Cited by 69
Nabilone pharmacotherapy for cannabis dependence: A randomized, controlled pilot study
Hill, K. P., Palastro, M. D., Gruber, S. A., Fitzmaurice, G. M., Greenfield, S. F., Lukas, S. E., & Weiss, R. D. (2017) · American Journal on Addictions · doi:10.1111/ajad.12622 · Cited by 62
A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers
Cooper, Z. D., Foltin, R. W., Hart, C. L., Vosburg, S. K., Comer, S. D., & Haney, M. (2012) · Addiction Biology · doi:10.1111/j.1369-1600.2012.00461.x · Cited by 62
Pharmacotherapy for the Treatment of Cannabis Use Disorder
Kondo, K. K., Morasco, B. J., Nugent, S. M., Ayers, C. K., O'Neil, M. E., Freeman, M., & Kansagara, D. L. (2020) · Annals of Internal Medicine · doi:10.7326/m19-1105 · Cited by 63
Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users
Herrmann, E. S., Cooper, Z. D., Bedi, G., Ramesh, D., Reed, S. C., Comer, S. D., Foltin, R. W., & Haney, M. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4298-6 · Cited by 60
Classic and non‐classic psychedelics for substance use disorder: A review of their historic, past and current research
Mendes, F. R., Costa, C. D. S., Wiltenburg, V. D., Morales-Lima, G., Fernandes, J. A. B., & Filev, R. (2022) · Addiction Neuroscience · doi:10.1016/j.addicn.2022.100025 · Cited by 67
Progress toward pharmacotherapies for cannabis-use disorder: an evidence-based review
Copeland, J., & Pokorski, I. (2016) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s89857 · Cited by 59
Novel Pharmacologic Approaches to Treating Cannabis Use Disorder
Balter, R. E., Cooper, Z. D., & Haney, M. (2014) · Current Addiction Reports · doi:10.1007/s40429-014-0011-1 · Cited by 54
Achieving Cannabis Cessation — Evaluating N-acetylcysteine Treatment (ACCENT): Design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network
McClure, E. A., Sonne, S. C., Winhusen, T. M., Carroll, K. M., Ghitza, U. E., McRae‐Clark, A. L., Matthews, A. G., Sharma, G., Veldhuisen, P. C. V., Vandrey, R. G., et al. (2014) · Contemporary Clinical Trials · doi:10.1016/j.cct.2014.08.011 · Cited by 50
Self-citation
Abstinence and reduced frequency of use are associated with improvements in quality of life among treatment‐seekers with cannabis use disorder
Brezing, C., Choi, C. J., Pavlicová, M., Brooks, D., Mahony, A. L., Mariani, J. J., & LEVIN, F. R. (2018) · American Journal on Addictions · doi:10.1111/ajad.12660 · Cited by 49
Self-citation
Systematic review of outcome domains and measures used in psychosocial and pharmacological treatment trials for cannabis use disorder
Lee, D. C., Schlienz, N. J., Peters, E. N., Dworkin, R. H., Turk, D. C., Strain, E. C., & Vandrey, R. G. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.10.020 · Cited by 49
Ketamine-facilitated behavioral treatment for cannabis use disorder: A proof of concept study
Azhari, N., Hu, H., O’Malley, K. Y., Blocker, M. E., Levin, F. R., & Dakwar, E. (2021) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2020.1808982 · Cited by 48
Self-citation
Gender differences in cannabis use disorder treatment: Change readiness and taking steps predict worse cannabis outcomes for women
Sherman, B. J., Baker, N. L., & McRae‐Clark, A. L. (2016) · Addictive Behaviors · doi:10.1016/j.addbeh.2016.04.014 · Cited by 54
Endocannabinoid signaling in psychiatric disorders: a review of positron emission tomography studies
Sloan, M. E., Grant, C. W., Gowin, J. L., Ramchandani, V. A., & Foll, B. L. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0081-z · Cited by 47
Reward-related Brain Response and Craving Correlates of Marijuana Cue Exposure
Goldman, M., Szucs-Reed, R. P., Jagannathan, K., Ehrman, R. N., Wang, Z., Li, Y., Suh, J. J., Kampman, K. M., O’Brien, C. P., Childress, A. R., et al. (2012) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e318273863a · Cited by 45
Potential therapeutic benefits of cannabinoid products in adult psychiatric disorders: A systematic review and meta-analysis of randomised controlled trials
McKee, K. A., Hmidan, A., Crocker, C. E., Lam, R. W. M., Meyer, J. H., Crockford, D. N., Trépanier, A., Aitchison, K. J., & Tibbo, P. G. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.05.044 · Cited by 44
Marijuana and the Pediatric Population
Dharmapuri, S., Miller, K., & Klein, J. D. (2020) · PEDIATRICS · doi:10.1542/peds.2019-2629 · Cited by 44
Pharmacotherapies for cannabis use disorder: A systematic review and network meta-analysis
Bahji, A., Meyyappan, A. C., Hawken, E. R., & Tibbo, P. G. (2021) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2021.103295 · Cited by 48
Psychosocial and pharmacological treatments for cannabis use disorder and mental health comorbidities: a narrative review
Lees, R., Hines, L. A., D’Souza, D. C., Stothart, G., Forti, M. D., Hoch, E., & Freeman, T. P. (2021) · Psychological Medicine · doi:10.1017/s0033291720005449 · Cited by 42
Time-course of the DSM-5 cannabis withdrawal symptoms in poly-substance abusers
Hesse, M., & Thylstrup, B. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-258 · Cited by 41
Cannabis and Mood Disorders
Lucatch, A. M., Coles, A. S., Hill, K. P., & George, T. P. (2018) · Current Addiction Reports · doi:10.1007/s40429-018-0214-y · Cited by 40
Cognitive Behavioral Therapy and the Nicotine Transdermal Patch for Dual Nicotine and Cannabis Dependence: A Pilot Study
Hill, K. P., Toto, L. H., Lukas, S. E., Weiss, R. D., Trksak, G. H., Rodolico, J. M., & Greenfield, S. F. (2013) · American Journal on Addictions · doi:10.1111/j.1521-0391.2012.12007.x · Cited by 38
Quetiapine treatment for cannabis use disorder
Mariani, J. J., Pavlicová, M., Choi, C. J., Basaraba, C. N., Carpenter, K. M., Mahony, A. L., Brooks, D. J., Bisaga, A. M., Naqvi, N. H., Nunes, E. V., et al. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108366 · Cited by 38
Self-citation
Marijuana Dependence: Not Just Smoke and Mirrors
Ramesh, D., Schlosburg, J. E., Wiebelhaus, J. M., & Lichtman, A. H. (2011) · ILAR Journal · doi:10.1093/ilar.52.3.295 · Cited by 39
Which medications are suitable for agonist drug maintenance?
Darke, S. G., & Farrell, M. (2015) · Addiction · doi:10.1111/add.13158 · Cited by 36
Preclinical Studies of Cannabinoid Reward, Treatments for Cannabis Use Disorder, and Addiction-Related Effects of Cannabinoid Exposure
Panlilio, L. V., & Justinová, Z. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.193 · Cited by 39
Pharmacokinetic and Pharmacodynamic Profile of Supratherapeutic Oral Doses of Δ9‐THC in Cannabis Users
Lile, J. A., Kelly, T. H., Charnigo, R. J., Stinchcomb, A. L., & Hays, L. R. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.90 · Cited by 35
Youth marijuana use
Hadland, S. E., & Harris, S. K. (2014) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000114 · Cited by 35
Psychosocial and pharmacological interventions for the treatment of cannabis use disorder
Sabioni, P., & Le Foll, B. (2018) · F1000Research · doi:10.12688/f1000research.11191.1 · Cited by 37
The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysis
Wilson, J., Dobson, O., Langcake, A., Mishra, P., Bryant, Z., Leung, J., Dawson, D., Graham, M., Teesson, M., Freeman, T. P., et al. (2026) · The Lancet Psychiatry · doi:10.1016/s2215-0366(26)00015-5 · Cited by 34
Cannabis use, harms and the management of cannabis use disorder
Copeland, J., Clement, N., & Swift, W. (2014) · Neuropsychiatry · doi:10.2217/npy.13.90 · Cited by 33
Guanfacine decreases symptoms of cannabis withdrawal in daily cannabis smokers
Haney, M., Cooper, Z. D., Bedi, G., Herrmann, E., Comer, S. D., Reed, S. C., Foltin, R. W., & Levin, F. R. (2019) · Addiction Biology · doi:10.1111/adb.12621 · Cited by 31
Self-citation
The effect of high-dose dronabinol (oral THC) maintenance on cannabis self-administration
Schlienz, N. J., Lee, D. C., Stitzer, M. L., & Vandrey, R. G. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.02.022 · Cited by 31
Exercise as an adjunctive treatment for cannabis use disorder
Brellenthin, A. G., & Koltyn, K. F. (2016) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2016.1185434 · Cited by 31
Evidence-based Treatment Options in Cannabis Dependency
Walther, L., Gantner, A., Heinz, A., & Majiić, T. (2016) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2016.0653 · Cited by 30
Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration?
Lee, D., Karschner, E. L., Milman, G., Barnes, A. J., Goodwin, R. S., & Huestis, M. A. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.10.011 · Cited by 29
Impact of cannabis legalization on treatment and research priorities for cannabis use disorder
Sahlem, G. L., Tomko, R. L., Sherman, B. J., Gray, K. M., & McRae‐Clark, A. L. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1465398 · Cited by 32
Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: Results from a placebo-controlled randomised trial
Lintzeris, N., Mills, L., Dunlop, A. J., Copeland, J., McGregor, I. S., Bruno, R., Kirby, A. C., Montebello, M. E., Hall, M., Jefferies, M., et al. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108220 · Cited by 29
Cannabis and Pregnancy: A Review
Hayer, S., Mandelbaum, A. D., Watch, L., Ryan, K. S., Hedges, M. A., Manuzak, J. A., Easley, C. A., Schust, D. J., & Lo, J. O.-T. (2023) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000001159 · Cited by 30
Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries
Garay, R. P., Citrome, L., Samalin, L., Liu, C., Thomsen, M. S., Correll, C. U., Hameg, A., & Llorca, P. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1149164 · Cited by 30
A systematic review and meta-analysis of randomized controlled trials of cardiovascular toxicity of medical cannabinoids
Watanabe, A. H., Navaravong, L., Sirilak, T., Prasitwarachot, R., Nathisuwan, S., Page, R. L., II, & Chaiyakunapruk, N. (2021) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2021.03.013 · Cited by 27
Cannabis use disorder: from neurobiology to treatment
Foll, B. L., Tang, V. M., Rueda, S., Trick, L., & Boileau, I. (2024) · Journal of Clinical Investigation · doi:10.1172/jci172887 · Cited by 28
Effect of oral THC pretreatment on marijuana cue-induced responses in cannabis dependent volunteers
Lundahl, L. H., & Greenwald, M. K. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.01.046 · Cited by 25
Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol
Agonist Replacement for Cannabis Dependence (ARCD) study group, Bhardwaj, A. K., Allsop, D. J., Copeland, J., McGregor, I. S., Dunlop, A. J., Shanahan, M., Bruno, R., Phung, N., Montebello, M. E., et al. (2018) · BMC Psychiatry · doi:10.1186/s12888-018-1682-2 · Cited by 25
A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement Therapy for Cannabis Withdrawal Symptoms
Werneck, M. A., Kortas, G. T., de Andrade, A. G., & Castaldelli-Maia, J. M. (2018) · CNS Drugs · doi:10.1007/s40263-018-0577-6 · Cited by 25
Cannabinoids in the Treatment of Selected Mental Illnesses: Practical Approach and Overview of the Literature
Müller‐Vahl, K. (2024) · Pharmacopsychiatry · doi:10.1055/a-2256-0098 · Cited by 27
Cannabis : usage et dépendance
Dervaux, A., & Laqueille, X. (2012) · La Presse Médicale · doi:10.1016/j.lpm.2012.07.016 · Cited by 28
Non-abstinent treatment outcomes for cannabis use disorder
LEVIN, F. R., Mariani, J. J., Choi, C. J., Basaraba, C. N., Brooks, D. J., Brezing, C., & Pavlicová, M. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108765 · Cited by 22
Self-citation
Cannabis Use and Psychosis: Theme Introduction
Martinotti, G., Iorio, G. D., Sepede, G., Berardis, D. D., Risio, L. D., & Giannantonio, M. D. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802884627 · Cited by 22
Cannabis: The never-ending, nefarious nepenthe of the 21st century: What should the clinician know?
Greydanus, D. E., Kaplan, G., Baxter, L. E., Patel, D. R., & Feucht, C. L. (2015) · Disease-a-Month · doi:10.1016/j.disamonth.2015.01.004 · Cited by 22
Psychosocial and Pharmacological Interventions for the Treatment of Cannabis Use Disorder
Sabioni, P., & Foll, B. L. (2019) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.17202 · Cited by 22
Primary outcomes in two randomized controlled trials of treatments for cannabis use disorders
Peters, E. N., Nich, C., & Carroll, K. M. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.04.021 · Cited by 21
Open-label pilot study of quetiapine treatment for cannabis dependence
Mariani, J. J., Pavlicová, M., Mamczur, A. K., Bisaga, A. M., Nunes, E. V., & LEVIN, F. R. (2014) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2014.884102 · Cited by 19
Self-citation
Cannabinoid hyperemesis syndrome and cannabis withdrawal syndrome: a review of the management of cannabis-related syndrome in the emergency department
Mohammad, R., Exadaktylos, A. K., Santa, V. D., & Heymann, E. P. (2022) · International Journal of Emergency Medicine · doi:10.1186/s12245-022-00446-0 · Cited by 21
Do withdrawal-like symptoms mediate increased marijuana smoking in individuals treated with venlafaxine-XR?
Kelly, M. A., Pavlicová, M., Glass, A., Mariani, J. J., Bisaga, A. M., Sullivan, M. A., Nunes, E. V., & LEVIN, F. R. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.06.040 · Cited by 19
Self-citation
Plasma Cannabinoid Concentrations During Dronabinol Pharmacotherapy for Cannabis Dependence
Milman, G., Bergamaschi, M. M., Lee, D., Mendu, D. R., Barnes, A. J., Vandrey, R. G., & Huestis, M. A. (2013) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e3182a5c446 · Cited by 18

Authors: Levin, F. R., Mariani, J. J., Brooks, D. J., Pavlicova, M., Cheng, W., & Nunes, E. V.
Affiliations: New York State Psychiatric Institute (US)
Corresponding author: Levin, Frances R.
ORCID: Levin, Frances R.
Mariani, John J.
Cheng, Wendy
Nunes, Edward V.
Venue: Drug and Alcohol Dependence
Publisher: Elsevier BV
Published: 2011-07
Volume: 116
Issue: 1-3
Pages: 142-150
ISSN: 0376-8716 (ISSN-L)
DOI: 10.1016/j.drugalcdep.2010.12.010
PMC: PMC3154755
OpenAlex: W1979308736
Cited by: 232
References: 64
Citations by year: 2026: 12 · 2025: 7 · 2024: 17 · 2023: 15 · 2022: 25 · 2021: 15 · 2020: 13 · 2019: 12 · 2018: 23 · 2017: 11 · 2016: 14 · 2015: 19 · 2014: 20 · 2013: 9 · 2012: 17
FWCI: 11.28
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Drug and Alcohol Dependence (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: U.S. Public Health Service (K02 000465)
National Institute on Drug Abuse (K24DA022412, P50DA009236, K24DA029647, T32DA007294)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
Keywords: dronabinol, cannabis use disorder, delta-9-tetrahydrocannabinol, treatment retention, withdrawal symptoms, motivational enhancement therapy, abstinence, drug safety and tolerability
MeSH terms: Adult, Cannabinoids, Marijuana Abuse, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Marijuana Smoking, Middle Aged, Placebos, Psychotherapy, Psychotropic Drugs, Substance Withdrawal Syndrome, Dronabinol, Behavior, Addictive

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks